Sr. Engineer I, Manufacturing Science and Technology
Sana Biotechnology, Inc.Highlight
Summary
About the Role
About You
- MS in Chemical, Biological, or Biomedical Engineering plus 7 years of relevant experience or equivalent combination of education and work experience.
- More than 4 years of experience with mammalian cell culture, including 1 year in cell therapy.
- Experience leading technology transfers to an external CDMO, preferably of cell therapy processes.
- Detail-oriented with good problem-solving, technical writing, and verbal communication skills.
- Knowledge of PSC and pancreatic islet biology.
- Experience scaling-up a cell therapy manufacturing process to support phase 1 clinical trials.
- Familiarity with cGMP requirements and working in a regulated environment.
- Working knowledge of statistical design of experiments (DoE) and RCA.
- Experience with bioreactors, controlled-rate freezers, and other cell therapy equipment.
Benefits
- Generous health coverage for employees and their families.
- Ample paid time off including holidays, vacation, sick time, and parental leave.
- Short- and long-term disability insurance.
- 401(k) Plan with an immediately vested employer match.
- Tuition Reimbursement and Student Loan Repayment.
- Employee Stock Purchase Plan and commuter subsidy.
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.